Commonwealth of Pennsylvania Public School Empls Retrmt SYS Lowers Stock Position in Boston Scientific Corporation $BSX

Commonwealth of Pennsylvania Public School Empls Retrmt SYS cut its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 3.1% during the fourth quarter, HoldingsChannel.com reports. The fund owned 344,824 shares of the medical equipment provider’s stock after selling 10,999 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Boston Scientific were worth $32,879,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Forsta AP Fonden grew its position in shares of Boston Scientific by 2.5% during the fourth quarter. Forsta AP Fonden now owns 375,200 shares of the medical equipment provider’s stock worth $35,775,000 after acquiring an additional 9,100 shares during the last quarter. Norges Bank purchased a new position in shares of Boston Scientific during the fourth quarter worth approximately $2,199,395,000. Eurizon Capital SGR S.p.A. purchased a new position in shares of Boston Scientific during the fourth quarter worth approximately $123,890,000. Fideuram Asset Management Ireland dac purchased a new position in shares of Boston Scientific during the fourth quarter worth approximately $3,118,000. Finally, National Pension Service grew its position in shares of Boston Scientific by 8.6% during the fourth quarter. National Pension Service now owns 3,761,615 shares of the medical equipment provider’s stock worth $358,670,000 after acquiring an additional 296,409 shares during the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on BSX shares. Oppenheimer set a $90.00 target price on shares of Boston Scientific in a research report on Thursday, April 23rd. Robert W. Baird set a $70.00 price target on Boston Scientific in a report on Thursday. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Boston Scientific in a report on Thursday. Argus raised Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating and set a $112.00 price target on shares of Boston Scientific in a report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $87.46.

Boston Scientific Stock Performance

NYSE:BSX opened at $48.32 on Monday. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a fifty-two week low of $48.13 and a fifty-two week high of $109.50. The stock has a market cap of $71.82 billion, a PE ratio of 20.22, a price-to-earnings-growth ratio of 0.89 and a beta of 0.56. The firm’s fifty day simple moving average is $60.23 and its 200-day simple moving average is $78.46.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. During the same period in the prior year, the company posted $0.75 EPS. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Analysts expect that Boston Scientific Corporation will post 3.37 earnings per share for the current fiscal year.

Boston Scientific declared that its board has initiated a stock repurchase program on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s leadership believes its stock is undervalued.

Insider Transactions at Boston Scientific

In related news, Director Edward J. Ludwig purchased 3,580 shares of the stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the purchase, the director directly owned 25,359 shares in the company, valued at $1,437,348.12. This trade represents a 16.44% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director David C. Habiger purchased 2,250 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average cost of $55.92 per share, with a total value of $125,820.00. Following the purchase, the director directly owned 13,878 shares in the company, valued at approximately $776,057.76. The trade was a 19.35% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 9,800 shares of company stock valued at $554,012 in the last ninety days. 0.34% of the stock is currently owned by company insiders.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Negative Sentiment: Wells Fargo downgraded Boston Scientific to Equal Weight/hold and lowered its outlook on the stock, citing rising uncertainty around the company’s electrophysiology business and WATCHMAN growth. Wells Fargo cuts Boston Scientific to ’Equal Weight’ on Watchman slowdown
• Negative Sentiment: Reuters reported Boston Scientific hit a two-year low after flagging weaker demand for its WATCHMAN heart device, adding to investor concern that a core growth driver is slowing. Boston Scientific hits two-year low after flagging weaker demand for heart device
• Negative Sentiment: The company’s 2026 guidance was reiterated, but investors viewed it as underwhelming given the slowdown in WATCHMAN and softer urology demand, which hurt sentiment further. Stock Market Today, May 27: Boston Scientific Plunges After Reiterating Underwhelming Full Year Growth Guidance
• Negative Sentiment: Analyst commentary from Zacks said Boston Scientific and Abbott both posted solid growth, but Boston Scientific is facing mounting operational pressures, which may be limiting upside near term. BSX vs. ABT: Which Medical Stock Has More Upside Potential?
• Positive Sentiment: Despite the selloff, Boston Scientific’s clinical pipeline remains active, with updates on the FARAPULSE PFA atrial fibrillation study and a painful diabetic neuropathy trial milestone that could support future growth. Boston Scientific Advances FARAPULSE PFA Study in Atrial Fibrillation Boston Scientific Nears Key Data Milestone in Painful Diabetic Neuropathy Trial
• Positive Sentiment: Unusually large call-option buying suggests some traders are positioning for a rebound in BSX after the recent weakness. Investors Buy Large Volume of Call Options on Boston Scientific (NYSE:BSX)

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.